Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Arthritis, Rheumatoid,Arthritis, Juvenile Rheumatoid,Psoriasis,Arthritis, Psoriatic,Spondylitis, Ankylosing,Uveitis,Colitis, Ulcerative,Crohn Disease,Hidradenitis Suppurativa, Date of authorisation: 13/02/2020, Status: Authorised

2020 ◽  
Author(s):  
Sign in / Sign up

Export Citation Format

Share Document